2.3. Statistical Analysis
EVENTS
For this analysis, data were pooled within treatment types (combined dupilumab 200 and 300 mg q2w and combined matched placebo groups). Annualized severe exacerbation rates over the 52-week treatment period were assessed using a negative binomial model, with the total number of events with onset from randomization up to visit 18 or the last contact date (whichever came earlier) as the response variable. The pooled treatment groups, age, region (pooled country), baseline eosinophil strata, baseline ICS dose level, and the number of severe exacerbation events within 1 year prior to the study were included in the model as covariates and the log-transformed standardized observation duration as an offset variable. Change from baseline in FEV